Latest news with #ChinaNationalIntellectualPropertyAdministration
Business Wire
3 days ago
- Business
- Business Wire
bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. "With lung cancer representing a major health burden globally and particularly in China, securing this intellectual property positions us well for future opportunities in one of the world's largest and most underserved healthcare markets." Share China represents a large prospective market for CyPath® Lung with more than 300 million people who smoke, or a third of the world's total smokers, according to the World Health Organization. The China cancer registry estimated 1.06 million new cases of lung cancer were diagnosed in 2022. 'This patent is another step forward in our strategy to safeguard and expand the reach of our proprietary diagnostic platform internationally,' said Maria Zannes, President and CEO of bioAffinity Technologies. 'With lung cancer representing a major health burden globally and particularly in China, securing this intellectual property positions us well for future opportunities in one of the world's largest and most underserved healthcare markets. It reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives.' The newly allowed Chinese patent—titled 'System and Method for Determining Lung Health'—protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. In the study, CyPath® Lung detected all forms of lung cancer and 80% of cancers that were Stage 1. This newly allowed patent complements bioAffinity's expanding global patent estate, which now includes multiple patents in the U.S, China, Japan, Australia, Mexico, Canada and the EU. About CyPath® Lung CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market the CyPath® Lung technology in China. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to derive benefits from the patent and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Yahoo
09-07-2025
- Business
- Yahoo
Microbot Medical Secures China Patent for LIBERTY System, Eyes Q3 2025 US Launch
Microbot Medical Inc. (NASDAQ:MBOT) is one of the best-performing NASDAQ stocks according to analysts. On June 17, Microbot Medical announced that it had been granted a patent in China by the China National Intellectual Property Administration/CNIPA. The patent covers the robotic manipulation of a surgical tool handle and is a step in the company's global intellectual property/IP expansion strategy. LIBERTY System now includes 9 patents granted globally and 59 patent applications pending. The LIBERTY system is a single-use and fully disposable endovascular robotic system for assisting surgeons in performing minimally invasive procedures within blood vessels. Close-up of a robotic endoluminal surgery device performing a procedure in an operating room. The patent portfolio protects the capabilities of the LIBERTY System. Microbot Medical's focus remains on the US market, where it is preparing for the anticipated commercial launch of the LIBERTY Endovascular Robotic System in Q3 2025. Microbot Medical Inc. (NASDAQ:MBOT) is a clinical-stage medical device company that researches, designs, and develops robotic endoluminal surgery devices targeting the minimally invasive surgery space in Israel and the US. While we acknowledge the potential of MBOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Star
13-06-2025
- General
- The Star
Chinese man impresses many by building lift to access fifth-floor home
An elderly resident in northeastern China has earned the nickname 'Iron Man of his residential complex' for creating a unique lift that he has used for the past five years. However, after his ingenious invention gained attention online and captivated many internet users, local authorities in Huludao, Liaoning province, along with the residential committee, urged him to dismantle it, as reported by the Liaoshen Evening News. The silver-haired innovator, known as Wang, constructed his lift – a design reminiscent of a cable car – in 2020 when he could no longer tolerate climbing up the stairs to reach his fifth-floor home. Wang dedicated an entire year to the preparation of this project, conducting research online and purchasing materials, which amounted to a total cost of 8,000 yuan (US$1,100). He designed, welded, and assembled the entire system entirely by himself. This compact lift is small enough to accommodate only a chair, with a cable connecting Wang's window to a lamp post located on the street near his residential block. In a noteworthy achievement, Wang applied for and successfully obtained a patent for his invention from the China National Intellectual Property Administration in October 2020. 'My lift operates in silent mode, allowing trucks to pass beneath it, and it doesn't disrupt the daily lives of residents in the community,' Wang was quoted as saying. He claimed he was unaware of any safety risks associated with his creation. A neighbour, whose identity was not disclosed in the report, mentioned that she often saw Wang using tools to repair and maintain the lift. An official from the municipal market supervision bureau stated they had only discovered the existence of this unusual lift once it went viral on social media. 'After reviewing the Special Equipment Security Law, we determined that it does not qualify as special equipment,' the official, who wished to remain unnamed, explained. Together with members of the residential committee, this official spent several days persuading Wang to remove his lift in early June. The story sparked a lively debate among mainland internet users, amassing 5 million views on a popular social media platform. 'What a genius! I've dreamed about doing this but cannot execute it,' one online commenter remarked. 'Can you believe a makeshift lift has been in use for five years? It looks so dangerous!' another user commented. Another individual posed the question: 'After dismantling it, what plans do they have to address the issue of elderly residents being unable to climb stairs?' - SOUTH CHINA MORNING POST
India Today
09-05-2025
- Science
- India Today
Baidu in China working on AI that will let humans understand animals
Have you ever wondered what your cat or dog is trying to say? Sounds ambitious, right? Well, Baidu is now working on something that might help with this. For those who don't know, Baidu is a Chinese tech company founded in 2000, and is known for running the country's biggest search engine. It wants to use AI to understand what animals are feeling or trying to say. The company recently filed a patent with the China National Intellectual Property Administration that describes a special system that could change animal sounds into human language. This system would use a mix of animal sounds, behaviour, and body signals to guess the animal's emotions and then turn those emotions into words we can to Baidu's patent, the system will first collect sounds made by animals, such as meows, barks or other vocalisations. It will also look at their behaviour, like how they move or act, along with body data like heart rate. All of this information will be processed together using AI to figure out what the animal might be feeling — like happiness, fear or hunger. Then, the system — in theory — would match these feelings with words or phrases in human language. This could allow people to talk with their pets in a whole new said in the patent that the system would allow 'deeper emotional communication and understanding between animals and humans, improving the accuracy and efficiency of cross-species communication.' When asked about when this product might be ready, a Baidu spokesperson said, 'There has been a lot of interest in the filing of our patent application. Currently, it is still in the research phase.'advertisementBaidu is not the only one working on this idea. Around the world, other scientists are also trying to use AI to study how animals communicate. For example, Project CETI (Cetacean Translation Initiative) is studying how sperm whales talk to each other using sounds. Another group called the Earth Species Project is also working to decode animal communication using technology. That project is supported by big names, including LinkedIn co-founder Reid news of Baidu's new animal translation patent came out, many folks on Chinese social media started talking. Some were excited, while others weren't so sure about the whole idea. A Weibo user wrote, 'While it sounds impressive, we'll need to see how it performs in real-world applications.'
Asahi Shimbun
09-05-2025
- Business
- Asahi Shimbun
China's Baidu looks to patent AI system to decipher animal sounds
A Baidu sign is seen at the World Artificial Intelligence Conference (WAIC) in Shanghai, China July 6, 2023. (REUTERS) BEIJING--Ever wished you could understand what your cat is trying to tell you? A Chinese tech company is exploring whether it's possible to translate those mysterious meows into human language using artificial intelligence. Baidu, owner of China's largest search engine, has filed a patent with China National Intellectual Property Administration proposing a system to convert animal vocalizations into human language, according to a patent document published this week. Scientists have long attempted to decode animal communication, and Baidu's patent represents the latest effort to leverage AI to do so. The document says the system will collect animal data, including vocal sounds, behavioral patterns, and physiological signals, which will be preprocessed and merged before an AI-powered analysis designed to recognize the animal's emotional state. The emotional states would then be mapped to semantic meanings and translated into human language. The system could allow 'deeper emotional communication and understanding between animals and humans, improving the accuracy and efficiency of cross-species communication,' Baidu said in the patent document. 'There has been a lot of interest in the filing of our patent application,' a Baidu spokesperson said when asked how soon the company could turn the patent into a product. 'Currently, it is still in the research phase.' Baidu was among the first major Chinese companies to invest heavily in AI following the 2022 debut of OpenAI's ChatGPT. It unveiled its latest AI model, Ernie 4.5 Turbo, last month, saying it matched the industry's best in several benchmark tests. However, the Ernie chatbot has struggled to gain traction amid fierce competition. A number of efforts are underway outside China to try and interpret what animals want to convey. International researchers at Project CETI (Cetacean Translation Initiative) have been using statistical analysis and AI since 2020 to understand how sperm whales communicate, while the Earth Species Project, a non-profit founded in 2017 whose backers include LinkedIn's Reid Hoffman, is also trying to use AI to decode animal communication. Local media reports about Baidu's patent application sparked discussion on Chinese social media platforms late on Wednesday. While some were excited about the possibility of eventually being better able to understand their pets, others were skeptical. 'While it sounds impressive, we'll need to see how it performs in real-world applications,' commented a user on Weibo.
